Tsuruha Holdings Inc.
Tsuruha Holdings Inc. (3391.T) Stock Competitors & Peer Comparison
See (3391.T) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 3391.T | ¥2,261.50 | +2.75% | 110.1B | 33.96 | ¥66.60 | +2.20% |
| 3088.T | ¥2,463.00 | +1.99% | 980.1B | 17.61 | ¥139.83 | +1.91% |
| 3141.T | ¥3,160.00 | -2.86% | 656B | 34.25 | ¥92.27 | +1.14% |
| 7649.T | ¥3,398.00 | +0.68% | 614.9B | 14.92 | ¥227.80 | +1.03% |
| 3349.T | ¥6,875.00 | +2.63% | 544.9B | 17.46 | ¥393.86 | +1.09% |
| 9989.T | ¥3,959.00 | +0.64% | 463.1B | 14.58 | ¥271.62 | +3.28% |
| 3549.T | ¥3,679.00 | +1.04% | 350.5B | 19.72 | ¥186.58 | +0.41% |
| 3148.T | ¥3,235.00 | +0.15% | 209B | 12.63 | ¥256.17 | +2.44% |
| 9627.T | ¥5,486.00 | +0.15% | 192.4B | 20.73 | ¥264.59 | +1.46% |
| 9267.T | ¥3,870.00 | +0.26% | 118B | 15.71 | ¥246.27 | +0.34% |
Stock Comparison
3391.T vs 3088.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 3088.T has a market cap of 980.1B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 3088.T trades at ¥2,463.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 3088.T's P/E ratio is 17.61. In terms of profitability, 3391.T's ROE is +0.12%, compared to 3088.T's ROE of +0.11%. Regarding short-term risk, 3391.T is less volatile compared to 3088.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 3088.T's competition here
3391.T vs 3141.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 3141.T has a market cap of 656B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 3141.T trades at ¥3,160.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 3141.T's P/E ratio is 34.25. In terms of profitability, 3391.T's ROE is +0.12%, compared to 3141.T's ROE of +0.08%. Regarding short-term risk, 3391.T is less volatile compared to 3141.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 3141.T's competition here
3391.T vs 7649.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 7649.T has a market cap of 614.9B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 7649.T trades at ¥3,398.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 7649.T's P/E ratio is 14.92. In terms of profitability, 3391.T's ROE is +0.12%, compared to 7649.T's ROE of +0.16%. Regarding short-term risk, 3391.T is less volatile compared to 7649.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 7649.T's competition here
3391.T vs 3349.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 3349.T has a market cap of 544.9B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 3349.T trades at ¥6,875.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 3349.T's P/E ratio is 17.46. In terms of profitability, 3391.T's ROE is +0.12%, compared to 3349.T's ROE of +0.12%. Regarding short-term risk, 3391.T is less volatile compared to 3349.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 3349.T's competition here
3391.T vs 9989.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 9989.T has a market cap of 463.1B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 9989.T trades at ¥3,959.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 9989.T's P/E ratio is 14.58. In terms of profitability, 3391.T's ROE is +0.12%, compared to 9989.T's ROE of +0.11%. Regarding short-term risk, 3391.T is more volatile compared to 9989.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3391.T.Check 9989.T's competition here
3391.T vs 3549.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 3549.T has a market cap of 350.5B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 3549.T trades at ¥3,679.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 3549.T's P/E ratio is 19.72. In terms of profitability, 3391.T's ROE is +0.12%, compared to 3549.T's ROE of +0.13%. Regarding short-term risk, 3391.T is less volatile compared to 3549.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 3549.T's competition here
3391.T vs 3148.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 3148.T has a market cap of 209B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 3148.T trades at ¥3,235.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 3148.T's P/E ratio is 12.63. In terms of profitability, 3391.T's ROE is +0.12%, compared to 3148.T's ROE of +0.12%. Regarding short-term risk, 3391.T is more volatile compared to 3148.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3391.T.Check 3148.T's competition here
3391.T vs 9627.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 9627.T has a market cap of 192.4B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 9627.T trades at ¥5,486.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 9627.T's P/E ratio is 20.73. In terms of profitability, 3391.T's ROE is +0.12%, compared to 9627.T's ROE of +0.07%. Regarding short-term risk, 3391.T is more volatile compared to 9627.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3391.T.Check 9627.T's competition here
3391.T vs 9267.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 9267.T has a market cap of 118B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 9267.T trades at ¥3,870.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 9267.T's P/E ratio is 15.71. In terms of profitability, 3391.T's ROE is +0.12%, compared to 9267.T's ROE of +0.14%. Regarding short-term risk, 3391.T is less volatile compared to 9267.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 9267.T's competition here
3391.T vs 3341.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 3341.T has a market cap of 116.8B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 3341.T trades at ¥3,910.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 3341.T's P/E ratio is 45.91. In terms of profitability, 3391.T's ROE is +0.12%, compared to 3341.T's ROE of +0.04%. Regarding short-term risk, 3391.T is less volatile compared to 3341.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 3341.T's competition here
3391.T vs 3034.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 3034.T has a market cap of 67.2B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 3034.T trades at ¥1,790.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 3034.T's P/E ratio is 8.95. In terms of profitability, 3391.T's ROE is +0.12%, compared to 3034.T's ROE of +0.12%. Regarding short-term risk, 3391.T is more volatile compared to 3034.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3391.T.Check 3034.T's competition here
3391.T vs 2664.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 2664.T has a market cap of 65.3B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 2664.T trades at ¥2,923.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 2664.T's P/E ratio is 14.13. In terms of profitability, 3391.T's ROE is +0.12%, compared to 2664.T's ROE of +0.04%. Regarding short-term risk, 3391.T is more volatile compared to 2664.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3391.T.Check 2664.T's competition here
3391.T vs 4931.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 4931.T has a market cap of 43.4B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 4931.T trades at ¥2,053.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 4931.T's P/E ratio is 17.06. In terms of profitability, 3391.T's ROE is +0.12%, compared to 4931.T's ROE of +0.12%. Regarding short-term risk, 3391.T is more volatile compared to 4931.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3391.T.Check 4931.T's competition here
3391.T vs 219A.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 219A.T has a market cap of 42.8B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 219A.T trades at ¥1,872.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 219A.T's P/E ratio is 46.74. In terms of profitability, 3391.T's ROE is +0.12%, compared to 219A.T's ROE of +0.08%. Regarding short-term risk, 3391.T is less volatile compared to 219A.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 219A.T's competition here
3391.T vs 7679.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 7679.T has a market cap of 39B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 7679.T trades at ¥2,007.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 7679.T's P/E ratio is 8.85. In terms of profitability, 3391.T's ROE is +0.12%, compared to 7679.T's ROE of +0.11%. Regarding short-term risk, 3391.T is more volatile compared to 7679.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3391.T.Check 7679.T's competition here
3391.T vs 8095.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 8095.T has a market cap of 19B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 8095.T trades at ¥471.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 8095.T's P/E ratio is 8.68. In terms of profitability, 3391.T's ROE is +0.12%, compared to 8095.T's ROE of +0.08%. Regarding short-term risk, 3391.T is more volatile compared to 8095.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3391.T.Check 8095.T's competition here
3391.T vs 3417.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 3417.T has a market cap of 18.4B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 3417.T trades at ¥1,350.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 3417.T's P/E ratio is 6.50. In terms of profitability, 3391.T's ROE is +0.12%, compared to 3417.T's ROE of +0.08%. Regarding short-term risk, 3391.T is less volatile compared to 3417.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 3417.T's competition here
3391.T vs 4350.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 4350.T has a market cap of 14.9B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 4350.T trades at ¥511.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 4350.T's P/E ratio is 9.91. In terms of profitability, 3391.T's ROE is +0.12%, compared to 4350.T's ROE of +0.05%. Regarding short-term risk, 3391.T is less volatile compared to 4350.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 4350.T's competition here
3391.T vs 3544.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 3544.T has a market cap of 11.7B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 3544.T trades at ¥846.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 3544.T's P/E ratio is 21.36. In terms of profitability, 3391.T's ROE is +0.12%, compared to 3544.T's ROE of +0.06%. Regarding short-term risk, 3391.T is more volatile compared to 3544.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3391.T.Check 3544.T's competition here
3391.T vs 4890.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 4890.T has a market cap of 10.7B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 4890.T trades at ¥413.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 4890.T's P/E ratio is -60.74. In terms of profitability, 3391.T's ROE is +0.12%, compared to 4890.T's ROE of -0.30%. Regarding short-term risk, 3391.T is less volatile compared to 4890.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 4890.T's competition here
3391.T vs 190A.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 190A.T has a market cap of 9.2B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 190A.T trades at ¥129.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 190A.T's P/E ratio is -4.96. In terms of profitability, 3391.T's ROE is +0.12%, compared to 190A.T's ROE of -0.54%. Regarding short-term risk, 3391.T is less volatile compared to 190A.T. This indicates potentially lower risk in terms of short-term price fluctuations for 3391.T.Check 190A.T's competition here
3391.T vs 2796.T Comparison March 2026
3391.T plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 3391.T stands at 110.1B. In comparison, 2796.T has a market cap of 5.9B. Regarding current trading prices, 3391.T is priced at ¥2,261.50, while 2796.T trades at ¥514.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
3391.T currently has a P/E ratio of 33.96, whereas 2796.T's P/E ratio is -39.45. In terms of profitability, 3391.T's ROE is +0.12%, compared to 2796.T's ROE of -0.02%. Regarding short-term risk, 3391.T is more volatile compared to 2796.T. This indicates potentially higher risk in terms of short-term price fluctuations for 3391.T.Check 2796.T's competition here